Suboxone Dental-Injury Evidence: What FDA, Studies, and MDL 3092 Actually Show

What FDA found in 2022

On January 12, 2022, FDA required new dental warnings for buprenorphine medicines dissolved in the mouth. The agency described reported tooth decay, cavities, oral infections, erosion, fractures, and tooth loss, including events in some patients without a known prior dental history. Its data summary identified 305 cases in adverse-event reports and medical literature through December 31, 2018, with a median time to diagnosis of about 24 months among the reported cases.

Those figures require two cautions. Passive reports do not provide a rate because total exposed patients and reporting completeness are unknown. And FDA expressly said buprenorphine remains an important treatment for opioid use disorder and pain whose benefits outweigh these risks. Patients should not abruptly stop medication: discontinuation can contribute to withdrawal, relapse, overdose, and death. Treatment changes belong with the prescribing clinician.

Which products and exposure route matter

The safety communication covers transmucosal products that dissolve under the tongue or against the cheek. It does not apply in the same way to injections or skin patches, because the prolonged local oral exposure differs. Suboxone film combines buprenorphine and naloxone and is one branded transmucosal product. The 2022 prescribing information added dental decay, caries, tooth fracture, and tooth loss among reported local reactions.

MDL 3092 is narrower than the agency-wide warning. The JPML transfer order and Northern District of Ohio page identify Suboxone buprenorphine/naloxone film products-liability actions. Plaintiffs allege that the film's acidity and time dissolving in the mouth contributed to erosion and decay and that warnings were inadequate; defendants contest liability. Generic buprenorphine use, tablets, and other brands raise product-identification issues that cannot be answered by the FDA warning alone.

What newer research contributes

A 2024 experimental study reported that buprenorphine and its metabolite accumulated in rat salivary glands, sustained oral-fluid exposure, and promoted Streptococcus mutans biofilm formation at high concentrations in vitro. That work offers a plausible mechanism worth testing, but animal pharmacokinetics and laboratory biofilm formation are not a direct measurement of cavities in people taking prescribed Suboxone film.

A 2025 retrospective claims study compared adults with opioid use disorder who received repeated transmucosal buprenorphine prescriptions with matched controls and evaluated new oral-health diagnoses over time. Observational data can test whether a signal appears in clinical populations, yet residual confounding remains important: baseline dental care, dry mouth, tobacco, diet, other medicines, access to dentists, and health conditions can affect risk. No single design resolves both general and individual causation.

What the federal court was doing in 2026

The JPML centralized the cases in February 2024. Case Management Order 12 later required census forms, medical, dental, and pharmacy or medication-treatment authorizations, plus records intended to establish use of brand-name Suboxone film and injury. An amended records order filed March 31, 2026 governs collection from health-care providers and facilities. These requirements show that a diagnosis and a medication recollection are not enough; the MDL is building documentary files.

A March 27, 2026 bellwether protocol set 2026 dates for plaintiff and defendant fact sheets, product-identification disputes, and selection of a core discovery pool. Selection is a sampling and discovery step, not a finding of causation or entitlement. The official court page does not announce a universal settlement, completed trial, or payout schedule as of July 10, 2026.

Evidence that can clarify an individual history

Useful records include pharmacy fills identifying brand, formulation, dose, and duration; prescribing notes; dental charts and X-rays before, during, and after use; periodontal and restorative records; extractions, crowns, implants, and billing; oral-hygiene history; dry-mouth symptoms; tobacco and dietary factors; and other medicines. A timeline can test whether disease emerged after exposure while also documenting baseline conditions and alternative explanations.

FDA recommends a baseline dental evaluation, regular checkups, and preventive planning. After the medicine fully dissolves, patients should gently rinse teeth and gums with water and swallow, then wait at least one hour before brushing. These are safety recommendations, not admissions about a lawsuit. A person should follow current clinical advice and consult the prescriber and dentist; legal deadlines and product proof require individualized review rather than a web eligibility promise.

Reader questions

Frequently asked questions